Literature DB >> 6817759

The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.

C J Fowler, T J Mantle, K F Tipton.   

Abstract

The kinetics of inhibition of rat liver mitochondrial monoamine oxidase by clorgyline, l-deprenyl and pargyline are consistent with a mechanism whereby a reversible interaction between the inhibitor and the enzyme active site under conditions of thermodynamic equilibrium is followed by a time-dependent formation of the covalently-bound enzyme-inhibitor adduct. The Ki value for the reversible interaction between clorgyline and monoamine oxidase A is about 1000 times lower than that towards the B-form of the enzyme, and this difference is sufficient to account for most, but not all, of the selectivity of the inhibition caused by this compound. The Ki value of the monoamine oxidase B selective inhibitor l-deprenyl towards that form of the enzyme is only about 40-fold lower than that towards the A-form. However, in this case, the rate of formation of the irreversible adduct is considerably faster for the B-form than for the A-form and this makes a major contribution to the selectivity of this compound. Pargyline shows a Ki value towards monoamine oxidase B that is only 8 times lower than that towards the A-form and in this case the rates of formation of the enzyme-inhibitor adducts are similar. The significance of these results are discussed in terms of the selective inhibition of monoamine oxidase.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817759     DOI: 10.1016/0006-2952(82)90575-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor.

Authors:  Matic Pavlin; Janez Mavri; Matej Repič; Robert Vianello
Journal:  J Neural Transm (Vienna)       Date:  2013-04-02       Impact factor: 3.575

Review 2.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

Review 3.  90 years of monoamine oxidase: some progress and some confusion.

Authors:  Keith F Tipton
Journal:  J Neural Transm (Vienna)       Date:  2018-04-10       Impact factor: 3.575

4.  Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition.

Authors:  V Pérez; J L Marco; E Fernández-Alvarez; M Unzeta
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Species differences in the selective inhibition of monoamine oxidase (1-methyl-2-phenylethyl)hydrazine and its potentiation by cyanide.

Authors:  Zakia Ben Ramadan; Maria L Wrang; Keith F Tipton
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

6.  Purification and characterization of polyamine oxidase from Ascaris suum.

Authors:  S Müller; R D Walter
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

7.  N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.

Authors:  F Karoum
Journal:  Br J Pharmacol       Date:  1987-02       Impact factor: 8.739

8.  Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B.

Authors:  Anup K Upadhyay; Dale E Edmondson
Journal:  Biochemistry       Date:  2009-05-12       Impact factor: 3.162

Review 9.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

10.  Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation.

Authors:  Jason Rihel; David A Prober; Anthony Arvanites; Kelvin Lam; Steven Zimmerman; Sumin Jang; Stephen J Haggarty; David Kokel; Lee L Rubin; Randall T Peterson; Alexander F Schier
Journal:  Science       Date:  2010-01-15       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.